Cas12

HuidaGene Therapeutics recently announced that the FDA has granted Orphan Drug Designation to its CRISPR-based therapeutic candidate, HG302. The...

Cas12a chRDNA - A Novel Approach to Gene-Editing...

Mar. 6, 2023

Founded in 2011, Caribou Biosciences is developing novel allogeneic CAR-T cell and CAR-natural killer cell therapies to treat cancer. The UC Berkeley...

Catch up on CRISPR COVID-19 Diagnostics

Aug. 10, 2021

As the COVID-19 pandemic continues to evolve with fluctuating restrictions worldwide, mass vaccine rollouts and the emergence of new variants, it's...

CRISPR Diagnostics Update: Cas12a-based SARS-CoV-2...

May. 19, 2021

This week’s update looks at a CRISPR-Cas12a-based detection method, developed in China as a confirmatory tool to aid SARS-CoV-2 diagnosis.

Cas12

Transfusion-Dependent Beta-Thalassemia, TDT, (NCT06041620)
Sponsors:
Institute of Hematology & Blood Diseases Hospital, China

IND Enabling

Phase I

Phase II

Phase III

CRISPR SARS-CoV-2 Detection platform for COVID-19 Disease
Sponsors:
Mammoth Biosciences